DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity-Reference-Cited by-同舟云学术

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

Published:2010-03-05 Issue:1 Volume:67 Page:49-56
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Yang Chen Guang,Ciccolini Joseph,Blesius Aurore,Dahan Laetitia,Bagarry-Liegey Danielle,Brunet Caroline,Varoquaux Arthur,Frances Nicolas,Marouani Hafedh,Giovanni Antoine,Ferri-Dessens Rose-Marie,Chefrour Mohamed,Favre Roger,Duffaud Florence,Seitz Jean-François,Zanaret Michel,Lacarelle Bruno,Mercier Cédric

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-010-1282-4.pdf

Reference36 articles.

1. Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN (1994) Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648–2653

2. Budach W, Hehr T, Budach V, Belka C, Dietz K (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28

3. Choong N, Vokes E (2008) Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin 58:32–53

4. Chua D, Wei WI, Sham JS, Au GK (2008) Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 38:244–249

5. Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, Dales JP, Durand A, Milano G, Seitz JF, Lacarelle B (2006) Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol 58:272–275

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?;British Journal of Clinical Pharmacology;2023-03-30

2. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency;European Journal of Cancer;2023-03

3. Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis;Pharmaceutics;2022-10-06

4. Capecitabine—A “Permanent Mission” in Head and Neck Cancers “War Council”?;Journal of Clinical Medicine;2022-09-23

5. Mesenchymal stem cell‑derived exosomes loaded with 5‑Fu against cholangiocarcinoma in vitro;Molecular Medicine Reports;2022-05-09